Shire Human Genetic Therapies Inc.
Division of Takeda Pharmaceutical Co. Ltd.
www.shire.com
Latest From Shire Human Genetic Therapies Inc.
Interview: Orchard's Gene Therapies Bear Fruit With $110m Financing
The UK firm has attracted more top-tier investors who are clearly impressed with its gene therapy for bubble baby syndrome and a high-quality pipeline in other very rare diseases.
APPOINTMENTS: J&J, Adherium, Tizona Therapeutics, Pliant, ProclaRx, Biocom, FORMA, VAXIMM
This week’s announcements include board appointments by Biocom, Pliant Therapeutics and ProclaRx; senior appointments by FORMA Therapeutics and Tizona Therapeutics and various appointments in Asia by China Healthcare Reform Office, Shanghai Pharmaceuticals and the Johnson & Johnson Innovation Center in Shanghai.
Deal Terminations Not The End Of The Road For Licensed Drugs
Post-deal termination, approximately 14% of the drugs from those alliances go on to be approved, and of those still in development, nearly two-thirds advance at least one phase. Third in a series of follow-ups to IN VIVO’s 2014 study comparing/contrasting likelihood of approval and up-front payments on alliances, and the outcomes of relevant deals.
Unpacking Lysosomal Storage: New Insights Drive Parkinson’s Drug Development
Investors and dealmakers are using recent discoveries about convergences between Gaucher’s disease and Parkinson’s in the lysosome to generate new therapeutic programs. Start-up Lysosomal Therapeutics thinks that the rare disorder can serve as a model system for developing new drugs to increase lysosomal function as a way to treat Parkinson’s disease and possibly other neurodegenerative disorders.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Metabolic Disorders
- Alias(es)
- Transkaryotic Therapies Inc.
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Takeda Pharmaceutical Co. Ltd.
- Senior Management
-
Gregory D Perry, SVP, CFO
John Conley, VP, Bus. Dev.
John B Edwards, VP, Mktg.
Whaijen Soo, MD, PhD, SVP, R&D
Sylvie Gregoire, PhD, Pres. - Contact Info
-
Shire Human Genetic Therapies Inc.
Phone: (617) 349-0200
700 Main St.
Cambridge, MA 02139
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice